Press Release
October 14, 2020

Immunome Completes $44.9 Million Public Offering


The Life Sciences Capital Markets team advised Ladenburg Thalmann and Chardan as book-running managers in connection with both Immunome’s (Nasdaq: IMNM) pricing and closing of its upsized initial public offering of 3,250,000 shares of common stock at a public offering price of $12 per share, and the full exercise of the underwriters' option to purchase an additional 487,500 shares of common stock at the public offering price, resulting in additional gross proceeds of approximately $5.9 million. After giving effect to the full exercise of the over-allotment option, the total number of shares sold by Immunome in the initial public offering was 3,737,500 shares and the gross proceeds were approximately $44.9 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immunome.

The Goodwin team was led by Peter Rodas.

For additional details on the offering, please read the initial pricing and full exercise of the overallotment press releases.